Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Melanoma 36Neoplasm Metastasis 12Carcinoma, Renal Cell 11Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 10Colorectal Neoplasms 7Carcinoma, Hepatocellular 7Carcinoma, Merkel Cell 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Carcinoma, Basal Cell 5Lymphoma, T-Cell, Cutaneous 4Lymphoma, T-Cell 4Endometrial Neoplasms 4Carcinoma, Transitional Cell 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma, Kaposi 3Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Esophageal Neoplasms 3Carcinosarcoma 3Breast Neoplasms 3Stomach Neoplasms 2Skin Neoplasms 2Sarcoma 2

Interventions

talimogene laherparepvec 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Nivolumab 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Eccrine Porocarcinoma × Specimen Handling × Dermatologic × Clear all
NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡